Physician profile
Mohan Nuthakki
NPI 1336331388
$812.83
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $632 · 2020: $44.68 · 2021: $90.25 · 2022: $14.42 · 2023: $13.53 · 2024: $18.01.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $31.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $31.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $148.61 | 2019 | |
| Rigel Pharmaceuticals, INC. | $119.08 | 2019-2021 | |
| Lilly USA, LLC | $90.32 | 2019 | |
| Novartis Pharmaceuticals Corporation | $85.24 | 2019-2021 | |
| Pharmacyclics LLC, An Abbvie Company | $63.66 | 2019 | |
| Daiichi Sankyo INC. | $54.20 | 2021-2024 | Enhertu |
| Pfizer INC. | $49.84 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $32.52 | 2019-2021 | |
| Foundation Medicine, INC. | $32.50 | 2019 | |
| Janssen Scientific Affairs, LLC | $24.15 | 2019 | |
| Eisai INC. | $22.78 | 2019 | |
| Genzyme Corporation | $20.00 | 2019 | |
| Agios Pharmaceuticals, INC. | $19.66 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.82 | 2020 | |
| Celgene Corporation | $13.75 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $11.50 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.20 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohan Nuthakki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.